MyoVista Measurements in Patients With Atherosclerosis and CAD

Completed

• Conditions: Atherosclerosis; Coronary Artery Disease (CAD)

• Registration Number: NCT02873052
• Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Brief Summary

The MyoVista system is a novel electrocardiogram technology that provides non-invasive assessment of myocardial abnormalities by analyzing energy changes at the cellular level of the myocardium.

Detailed Description

The MyoVista iECG Electrocardiograph is a diagnostic device used to process electrical signals transmitted through electrocardiograph electrodes and to detect ischemia abnormalities based on electrical waveform, patient data, demographics, algorithmic sensitivity and software based informatics. The MyoVista provides the clinician with a standard ECG conventional waveform, along with an additional report derived from the proprietary informatics exclusive to the MyoVista.

The device holds a lot of promise for early intervention to properly diagnose and treat patients under risk timely and effectively. The MyoVista captures and amplifies signals from the myocardial tissue. These signals are then processed and compared to an algorithm that looks for certain changes occurring in these processed waveforms. The changes that have been identified occur much sooner than those processed by a traditional electrocardiogram (ECG). These recordings focus on early detection of myocardial abnormalities by non-linear analysis of electrical activity and physiological phenomenon. This novel assessment might be capable of detecting subclinical myocardial dysfunction in a variety of heart diseases.

The study would compare MyoVista results to subclinical measures of atherosclerosis (CAC and CT angiography) in 200 subjects at risk for coronary disease. Correlations between the MyoVista reading and the presence of calcified plaque, soft plaque, CTA stenosis, will be determined.

This study has the potential to confirm MyoVista as a reliable and sensitive marker of atherosclerosis. Findings may provide a strong indication for the value of a MyoVista test to confirm CAD in clinical practice, and for the clinical application of MyoVista in management of coronary disease and atherosclerosis.

Study Timeline

• Study Start: 2015-09-01
• Study First Submitted: 2016-06-29
• Study First Submitted QC: 2016-08-16
• Study First Posted: 2016-08-19
• Primary Completion: 2019-09-22
• Study Completion: 2020-02-22
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-10
• Last Update Posted: 2024-10-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Male or female gender
• From (and inclusive of) ages of 18 to 80 years
• Body mass index (BMI) between 18 and 39.9 (kg/m2)
• Able to lie (supine) still comfortably on the back for at least 20 minutes

Read More

Exclusion Criteria

• Known history of cancer, other than non-melanoma skin cancer
• Known history of heart disease or heart rhythm abnormalities
• Known history of cardiovascular disease
• Known history of Peripheral Artery Disease (PAD)
• Known history of claudication
• History of amputation or loss of limb(s)

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ability of MyoVista to measures subclinical atherosclerosis	5 Months

Trial Locations

Locations (1)

Los Angeles Biomedical Research Institute; 🇺🇸 Torrance, California, United States